Navigation Links
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Date:10/3/2007

p>"These findings provide further evidence of the role of IL-12/23 in the pathogenesis of psoriasis and the promise that a new therapeutic approach like ustekinumab may hold for dermatologists and their patients living with this chronic, immune-related disease," said Craig Leonardi, MD, St. Louis University Medical School and lead investigator of the study. "The efficacy and safety data for ustekinumab in the treatment of psoriasis are exciting for the dermatology community."

At week 12 of this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial, 67 percent of patients treated with 45 mg ustekinumab (two 45 mg doses four weeks apart) and 76 percent of patients treated with 90 mg ustekinumab (two 90 mg doses four weeks apart), achieved PASI 75 compared with four percent of patients receiving placebo (P < 0.001 for each comparison versus placebo). Also at week 12, 42 percent of patients in the 45 mg ustekinumab dosing group and 51 percent of patients in the 90 mg ustekinumab dosing group achieved PASI 90, or nearly complete clearance of psoriasis, compared with one percent of patients receiving placebo (P < 0.001 for each comparison versus placebo). Similar response rates were observed in the placebo group 12 weeks after crossover to treatment with ustekinumab. After one additional dose at week 16, responses were maintained through week 28, which is consistent with the maintenance regimen of every 12-week dosing currently being evaluated in the Phase 3 program. Improvements in clinical measures were paralleled with improvements in quality of life measures.

"These findings show that by targeting IL-12/23 with ustekinumab, we may be able to offer dermatologists and patients a new, promising biologic therapy with an infrequent dosing regimen for the treatment of psoriasis," said Jerome A. Boscia, MD, senior vice president, Clinical Research and Development, Centocor, Inc. "We are encouraged by the results from the Phase 3 program and look
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  4WEB Medical announces the formal launch of the ... implants on the market today at this weekend,s ... Chicago .  The Osteotomy Truss System is ... with 74 size options included in one versatile set. ... 15 to 18 implant sizes, which limited a surgeon,s ...
(Date:9/19/2014)... -- UBM Medica US announces that  OncoTherapy ... oncologists and other clinicians gain a better understanding of ... therapies and immunotherapies, discusses some of the latest news ... Every September, Blood Cancer Awareness Month is ... cancers—helping to increase survival rates and improve the quality ...
(Date:9/19/2014)... SOUTH EASTON, Mass. , Sept. 19, 2014 ... the "Company") today announced it has received and ... throughput Barozyme HT48 instruments and has begun to ... believes the first instrument will be ready for ... will be built and released at a rate ...
Breaking Medicine Technology:4WEB Medical Unveils 3D-Printed Osteotomy Truss System 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
... implement advanced patient outcome analysis software to monitor health ... Global Health Research Foundation (GHRF) today ... the Westly Foundation to fund asthma treatment in California,s ... asthma cases in the state. The grant will help ...
... February 4 Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a ... it has concluded a proof of concept,study in ... technology. Eight healthy volunteers came for two visits, ... The insulin suppositories showed rapid insulin absorption and ...
Cached Medicine Technology:Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in California's Central Valley 2Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository 2
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), a leading ... The new site provides the latest reviews on ... Here, people can find a lot of information ... has recommended some excellent web hosting suppliers for ... web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ), keeps ...
(Date:9/20/2014)... PA (PRWEB) September 20, 2014 "As a ... in their tanks," said an inventor from Tamaqua, Pa. "The ... mounted on the backs of their chairs. My invention enables ... developed the Kam Oxygen Sensor to make it easier to ... that the user knows when the tank is low. It ...
(Date:9/20/2014)... Earlier this week, Home Depot revealed that up ... credit card information pilfered by hackers, surpassing the 40 million ... articles like this one published by Bloomberg on ... , “Most people tend to focus on how many ... to score a game,” says Joe Caruso, founder and CEO/CTO ...
(Date:9/20/2014)... September 20, 2014 Final Cut Pro ... the release of the Information theme for FCPX filmmakers. , ... to describe the Information theme,” says Christina Austin, CEO of ... look so professional.” , Information features easy to use controls ... of the environment. Change the background color, color of each ...
(Date:9/20/2014)... September 20, 2014 “Motherhood is a wonderful ... Snohomish in their latest article , “We know that ... you can—and that’s what we want to do as well.” ... need and should expect from their Family Physicians who practice ... of new motherhood. , To learn more about Community ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2
... respect for human life at all stagesSays science and ... stem cell research that do not destroy human embryosWASHINGTON, ... missed "an enormous opportunity to show how sound science ... and enrich each other," said Msgr. David Malloy, General ...
... protein linked to tumor growth for clues to better treatments ... have found that levels of the protein caveolin-1 found in ... predict a patient,s prognosis and may provide a pathway to ... a role in how cells absorb things, in the stromal ...
... LAS COLINAS, Texas , May 22 One very ... the greatest golfers ever to play the game. With his ... that same year) and 52 victories over the span of ... as a sports hall-of-famer is set.Byron Nelson strove for excellence ...
... Legacy Foundation(R) applauds today,s unanimous decision in ... . The U.S. Court of Appeals for the District of ... tobacco industry engaged in a pattern of widespread fraud and ... for a period of more than 50 years. In referring ...
... throughout Texas were stunned by the Texas Veterinary Medical ... bill to license and regulate large-scale commercial breeding facilities, ... the commercial interest of breeders over the welfare of ... said Cile Holloway, president of Texas Humane Legislation Network, ...
... of Affordable Healthcare Roundtable SeriesSAN FRANCISCO, May 22 ... healthcare premiums in California rose five times ... With healthcare costs continuing to rise in the Bay ... finding themselves driven out of healthcare coverage. Teva Pharmaceuticals, ...
Cached Medicine News:Health News:USCCB Submits Comments to NIH on Proposed Guidelines for Stem Cell Research 2Health News:USCCB Submits Comments to NIH on Proposed Guidelines for Stem Cell Research 3Health News:The Byron Nelson: Championship Philosophy, Timeless Excellence 2Health News:The Byron Nelson: Championship Philosophy, Timeless Excellence 3Health News:Statement by American Legacy Foundation(R): Findings of Decades of Massive Fraud by Tobacco Industry Upheld in U.S. Court of Appeals 2Health News:Statement by American Legacy Foundation(R): Findings of Decades of Massive Fraud by Tobacco Industry Upheld in U.S. Court of Appeals 3Health News:Statement by American Legacy Foundation(R): Findings of Decades of Massive Fraud by Tobacco Industry Upheld in U.S. Court of Appeals 4Health News:Veterinary Group Opposes Bill to Clean Up Puppy Mill Industry 2Health News:As Healthcare Costs Skyrocket, Local Leaders Gather to Seek a Solution 2
Anti-RSV IgG Assay (ELISA)....
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
Qualitative ELISA for the detection of rotavirus antigen....
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis....
Medicine Products: